Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience.
Katharine Louise LewisCollin K ChinKate ManosJohn CaseyNada HamadJulie CrawfordShir-Jing HoSamar IssaAndrew GriggPeter WoodMaher K GandhiBryan DoLoretta NastoupilEliza A HawkesChan Yoon Y CheahPublished in: British journal of haematology (2020)
Primary and secondary central nervous system lymphomas (PCNSL/SCNSL) are aggressive rare malignancies with dismal outcomes. Encouraging data have emerged from Phase I/II clinical trials treating relapsed/refractory PCNSL/SCNSL with ibrutinib. We analysed 33 patients who received ibrutinib, alone or with other therapies, for PCNSL (n = 9) or SCNSL (n = 24). The objective response rate was 58% (complete response 55%). The median progression-free survival and overall survival for patients with PCNSL were both 3·1 months; for SCNSL, 10·2 and 11·5 months respectively. Only one invasive fungal infection was observed, despite concurrent or recent use of dexamethasone 8-16 mg daily in 14 patients (42%). Ibrutinib has encouraging activity in these aggressive malignancies.
Keyphrases
- free survival
- chronic lymphocytic leukemia
- diffuse large b cell lymphoma
- clinical trial
- end stage renal disease
- ejection fraction
- acute myeloid leukemia
- newly diagnosed
- acute lymphoblastic leukemia
- low dose
- peritoneal dialysis
- prognostic factors
- randomized controlled trial
- cerebrospinal fluid
- high dose
- physical activity
- electronic health record
- squamous cell carcinoma
- machine learning
- locally advanced
- skeletal muscle
- study protocol
- patient reported
- childhood cancer